Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587497 | 0.87 | LMNA (1.00) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3591337 | 0.86 | LMNA (0.79) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3583994 | 0.80 | LMNA (0.69) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL19724720 | 0.78 | ALDH1A1 (0.59) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3455901 | 0.78 | LMNA (0.67) | LMNAALDH1A1HPGDRAB9APOLB | |
| SCHEMBL3586165 | 0.78 | LMNA (0.66) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3583279 | 0.78 | LMNA (0.66) | LMNARAB9AKMT2AMEN1POLB | |
| SCHEMBL3582787 | 0.77 | NPC1 (0.66) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3592945 | 0.76 | RAB9A (0.67) | LMNAALDH1A1HPGDRAB9AKMT2A | |
| SCHEMBL3587434 | 0.76 | LMNA (0.64) | LMNAALDH1A1RAB9AKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | claimed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | claimed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | claimed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | claimed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | claimed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | claimed |
| US-8541457-B2 | Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2013-09-24 | — | — | US | disclosed |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2540296-A1 | Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2013-01-02 | — | — | EP | disclosed |
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-17 | — | — | US | disclosed |
| EP-2029138-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007130075-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152187-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | LMNA 1423/4885ALDH1A1 927/4885HPGD 593/4885 |
| US-20130096056-A1 | AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, ACAT1 | LMNA 1399/4885ALDH1A1 910/4885HPGD 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.